Lynozyfic (Garadacimab-gxii)

Lynozyfic (garadacimab-gxii) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager used for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM) who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.

The recommended dosage should be administered intravenously according to the step-up schedule to reduce the incidence and severity of cytokine release syndrome (CRS). Continue treatment until there is evidence of disease progression or unacceptable toxicity. The recommended dosage of Garadacimab-gxii is step-up doses of 5 mg, 25 mg, and 200 mg, followed by 200 mg weekly for 10 doses, followed by 200 mg biweekly (every 2 weeks). In patients who have achieved and maintained VGPR or better at or after Week 24 and received at least 17 doses of 200 mg, decrease the dosing frequency to 200 mg every 4 weeks.

• Treatment with Garadacimab-gxii 5 mg/2.5 mL may cause CRS, a serious immune reaction that can cause fever, low blood pressure, and breathing complications. Monitor closely during and following the infusion, especially after the first dose. Treat CRS immediately if it arises during or after therapy.
• Life-threatening neurologic side effects, including tremors, confusion, or seizures, may happen. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) can develop. Monitor patients for changes in behavior or alertness. Quick intervention and stopping treatment may be required for serious neurologic symptoms.
• Treatment with this therapeutic drug may weaken the immune response. This may increase the risk of serious bacterial, viral, or fungal infections. Screen for infections before initiating treatment and monitor during therapy. Do not use in those with active infections until resolved. Immediately treat any infection symptoms.
• This medicine may be responsible for reducing white blood cell count, especially neutrophils, which increases the risk of infection. Monitor blood counts persistently and manage with dose changes or supportive care if required. Promptly evaluate any fever or infection signs in those with low neutrophils.
• Liver damage, including elevated liver enzymes, may occur. Regularly test liver function during treatment with Lynozyfic 200 mg/10 mL. Stop therapy in case liver enzyme levels increase significantly or in case liver injury is suspected. Those with pre-existing liver complications need to be monitored more frequently and closely.
• This therapeutic drug may cause harm to an unborn baby. Do not use it during pregnancy. Women of childbearing capacity should use effective contraception during treatment and for a period after. Discuss pregnancy risks with patients before starting treatment and advise against becoming pregnant during use.
• It is not specified if Garadacimab-gxii passes into human breast milk. Breastfeeding is not required during treatment and for a certain period afterward to avoid potential harm to a nursing baby. Discuss breastfeeding risks and safer feeding alternative options with the patient before starting.

What documents are required to import LYNOZYFIC to India?

LYNOZYFIC (garadacimab-gxii) injection can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is LYNOZYFIC available in India?

LYNOZYFIC (garadacimab-gxii injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Lynozyfic in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait,
• Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

LYNOZYFIC can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of LYNOZYFIC (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Lynozyfic 200 mg/10 mL injection price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source LYNOZYFIC (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Lynozyfic®?

Garadacimab-gxii is the Generic Name for the trade name drug Lynozyfic®.

What is the Manufacturer's Name of Lynozyfic®?

Lynozyfic® is manufactured by Regeneron Pharmaceuticals, Inc.

Is Lynozyfic approved by the FDA?

Yes, Lynozyfic is approved by the FDA. Date of first approval: July 2, 2025.

What is the dosage and form of Lynozyfic® supplied?

Lynozyfic is supplied for Injection: 5 mg/2.5 mL (2 mg/mL) single-dose vial and 200 mg/10 mL (20 mg/mL) single-dose vial for intravenous use.

What are the most common side effects of Lynozyfic® 200 mg/10 mL injection?

The most commonly reported side effects of Lynozyfic® are fatigue, musculoskeletal pain, cough, cytokine release syndrome, upper respiratory tract infection, nausea, diarrhea, pneumonia, headache, and dyspnea.

How much does Lynozyfic® 200 mg/10 mL injection cost in India?

Lynozyfic® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Lynozyfic prices may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Lynozyfic 200 mg/10 mL cost in India, please call/WhatsApp +91-9310090915 or send an email to info@indianpharmanetwork.in.

Can Lynozyfic® 200 mg/10 mL injections be available in SAARC countries?

Apart from Gulf countries, Lynozyfic® can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Lynozyfic® injection in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Lynozyfic® 200 mg/10 mL injection online in India?

Yes, one can buy Lynozyfic 200 mg/10 mL online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not yet registered or available in their country. We can help facilitate the legal supply of Lynozyfic® injection through legal channels.

What are the storage conditions of Lynozyfic® 200 mg/10 mL injections?

Store unopened vials of Lynozyfic® in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. It is not advisable to freeze or shake the medicine.